This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, G.-Z. Articles by Zhu, B. T. Search for Related Content PubMed PubMed Citation Articles by Han, G.-Z. Articles by Zhu, B. T.

Synergism between the Anticancer Actions of 2-Methoxyestradiol and Microtubule-Disrupting Agents in Human Breast Cancer

¹ Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina and ² Institute for Environmental Sciences, University of Shizuoka, Shizuoka, Japan

Requests for reprints: Bao Ting Zhu, Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Room 617, Coker Life Sciences Building, 700 Sumter Street, Columbia, SC 29208. Phone: 803-777-4802; Fax: 803-777-8356; E-mail: BTZhu{at}cop.sc.edu.

2-Methoxyestradiol (2-MeO-E₂), a well-known nonpolar endogenous metabolite of 17ß-estradiol, has strong antiproliferative, apoptotic, and antiangiogenic actions in vitro and in vivo at pharmacologic concentrations. We determined in the present study whether 2-MeO-E₂ can enhance the anticancer actions of paclitaxel or vinorelbine (two commonly used microtubule-disrupting agents) in several human breast cancer cell lines, including the estrogen receptor–positive MCF-7 and T-47D cells and the receptor-negative MDA-MB-435s and MDA-MB-231 cells. 2-MeO-E₂ in combination with paclitaxel or vinorelbine exhibited a synergistic anticancer effect in these human breast cancer cells in vitro, and this synergistic effect was more pronounced when each of the drugs was used at relatively low concentrations. Additional experiments using female athymic BALB/c nu/nu mice showed that p.o. administration of 2-MeO-E₂ at 30 mg/kg body weight, once a week for 6 weeks, markedly enhanced the activity of paclitaxel or vinorelbine against the growth of the estrogen receptor–negative MDA-MB-231 human breast cancer xenografts in these animals. By contrast, combination of 2-MeO-E₂ with 5-fluorouracil only had a partial additive effect against the growth of these cell lines in culture, and no synergistic effect was observed. Interestingly, when doxorubicin was used in combination with 2-MeO-E₂, the antiproliferative effect of 2-MeO-E₂ was somewhat antagonized by doxorubicin when it was present at high concentrations. Our results showed that 2-MeO-E₂ at nontoxic or subtoxic doses selectively enhanced the effects of certain microtubule-disrupting agents (such as paclitaxel and vinorelbine) against the growth of the receptor-negative human breast cancer cells in culture and also in athymic nude mice.

Key Words: 2-methoxyestradlol • paclitaxel • vinorelbine • breast cancer • chemotherapy

This article has been cited by other articles:

				S. Mesia-Vela, R. I. Sanchez, K. R. Reuhl, A. H. Conney, and F. C. Kauffman Phenobarbital Treatment Inhibits the Formation of Estradiol-Dependent Mammary Tumors in the August-Copenhagen Irish Rat J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 590 - 597. [Abstract] [Full Text] [PDF]

				A. Basu, V. P. Castle, M. Bouziane, K. Bhalla, and S. Haldar Crosstalk between Extrinsic and Intrinsic Cell Death Pathways in Pancreatic Cancer: Synergistic Action of Estrogen Metabolite and Ligands of Death Receptor Family. Cancer Res., April 15, 2006; 66(8): 4309 - 4318. [Abstract] [Full Text] [PDF]

				V. Vijayanathan, S. Venkiteswaran, S. K. Nair, A. Verma, T.J. Thomas, B. T. Zhu, and T. Thomas Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells. Clin. Cancer Res., April 1, 2006; 12(7 Pt 1): 2038 - 2048. [Abstract] [Full Text] [PDF]